Last week the World Health Organization (WHO) and the TB Alliance joined with pharmaceutical companies AstraZeneca, Bayer, Sanofi and Tibotec in an innovative agreement to share information about tuberculosis (TB) compounds in their drug pipelines and speed the development of new regimens, including the most promising multi-drug treatments, regardless of sponsor. Science Speaks sat down with Mel Spigelman, MD, president and chief executive officer of the TB Alliance, to discuss the new collaboration, which promising drug combinations are coming down the pipeline, and how their work is expediting the process.
More than 150,000 Americans with HIV remain unaware of infection, while PrEP uptake represents fraction of need
With an ambitious, but yet to be funded federal plan to end the American HIV epidemic within the next 10 years in front of Congress, about […]
50th Union World Conference on Lung Health: Vaccine candidate shows effectiveness in preventing active TB disease
HYDERABAD, INDIA – The world is one major step closer to a vaccine against tuberculosis, researchers said here, with results from a clinical trial of an […]
DRC Ebola PHEIC continues amid ongoing obstacles while vaccine approval represents “major milestone” for future responses
While the committee examining the Ebola epidemic in the Democratic Republic of Congo emerged today from its 5th meeting with the conclusion that transmissions of the […]
DRC, Liberia, Madagascar, Somalia and Ukraine account for nearly half of global measles cases Measles incidence increased in five regions around the world between 2016 and […]